Immuno-oncology combinations have faced disappointing clinical trial data of late, but positive news from Bristol-Myers Squibb Co.'s Phase III trial testing its PD-1 inhibitor Opdivo (nivolumab) and CTLA-4 inhibitor Yervoy (ipilimumab) in advanced renal cell cancer could swing the pendulum back in their favor.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?